Our Pipeline

WE ARE DEDICATED TO ADVANCING A NOVEL CLASS OF CONDITIONALLY-ACTIVATED PROINFLAMMATORY IMMUNE MODULATORS INTO CLINICAL DEVELOPMENT

CANDIDATE	Discovery	IND-Enabling	Phase 1	Phase 2
WTX-124
WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-2 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in multiple tumor types. WTX-124 is designed to include maintenance of full IL-2 potency, high affinity blockade of IL2 - IL2Rβ/IL2Rγ interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation. Preliminary monotherapy data from the Phase 1/1b clinical trial presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting established proof of mechanism for WTX-124 and the potential to be a differentiated next-generation IL-2 compound by showing immune cell activation in the tumor microenvironment (TME) and monotherapy clinical activity in an outpatient setting. We are currently enrolling patients in a first-in-human, Phase 1, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced solid tumors. For more information on this study, visit clinicaltrials.gov (Identifier NCT05479812).
WTX-330
WTX-330 is a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-12 therapy and maximize clinical benefit when administered as monotherapy in refractory and/or immunologically unresponsive tumors. WTX-330 is designed to include high affinity blockade of IL-12 – IL-12R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation. We are currently progressing WTX-330 in a Phase 1, multi-center, open-label trial evaluating WTX-330 as a monotherapy in patients with immunotherapy insensitive or resistant advanced or metastatic solid tumors or non-Hodgkin lymphoma. Enrollment is ongoing in dose-escalation. For additional information about the trial, please visit www.clinicaltrials.gov using the Identifier: NCT05678998.
JZP898 (Formerly WTX-613)
WTX-613 is a systemically delivered, conditionally activated Interferon alpha (IFNα) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IFNα therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors. Our INDUKINE^TM molecule is designed to include high efficiency blockade of IFNα – IFNR interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation. In preclinical studies, WTX-613 exhibits robust anti-tumor activity mediated through stimulation of a type I interferon immune response with excellent pharmacokinetics and tolerability.
WTX-712
WTX-712 is a systemically delivered, conditionally activated Interleukin-21 (IL-21) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-21 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors. In preclinical studies, WTX-712 treatment and subsequent release of IL-21 in the tumor leads to an anti-tumor phenotype through increased immune infiltration, improved CD8+ T cells polyfunctionality, increased GZMB secretion, and the transition of macrophages towards a M1-like (non-suppressive) phenotype.
WTX-518
WTX-518 is a systemically delivered, conditionally activated Interleukin-18 (IL-18) INDUKINE^TM molecule that is being developed to maximize the potential clinical benefit of IL-18 when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
Novel INDUKINE Molecules
We apply our PREDATOR^TM protein engineering technology platform to identify, design, optimize and validate new immuno-oncology, autoimmune and inflammatory disease product candidates.

Expanded Access Policy:

Expanded access, or compassionate use, is the use of an investigational product prior to regulatory approval and outside of a clinical trial. Werewolf does not currently have an expanded access program or compassionate use program for any of our investigational products. We understand that for people living with cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trials is the best path to meet our goal of providing new treatments to patients with cancer. We encourage any person with cancer interested in gaining access to our investigational therapies to consult their physician(s) regarding the possibility of participating in one of our clinical trials.